The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, to reduce cardiovascular risk in type 2 diabetes ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Avoiding sleep drugs would reduce older Americans' lifetime rate of falls by nearly 9% and brain decline by 2%, among other ...

By now, your news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the ...

On an overcast mid-October day, just inside the Third Avenue offices of We Heart Seattle, Executive Director Andrea Suarez ...

Certain medications, such as blood thinners, may interact with omega-3 supplements. Learn more about omega-3 interactions here.

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

Some products of arachidonic acid have already been well studied: the prostanoids formed by cyclooxygenases are central ...

A growing number of Americans are turning to therapy by text message, and new research suggests it can be just as effective ...

Over the last year San Francisco Chronicle Reporter Maggie Angst and Photographer Gabrielle Lurie spent time with Austin Draper, who suffers from recurring endocarditis, a heart infection caused by ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...